pba health ppok opha - · pdf file1 pba health ° ppok ° opha opioids with...
TRANSCRIPT
1
PBA Health ° PPOK ° OPHA
Opioids with Abuse‐Deterrent Properties and Claims (OADP)
By
Kelley Waara‐Wolleat, PharmD, MBA
2
Synergy Conference PBA HEALTH • PPOK • OPHA
Synergy Conference PBA HEALTH • PPOK • OPHA
Opioids with Abuse Deterrent Properties andClaims (OADP)
KelleyWaara Wolleat, PharmD, MBAAssociate Director, Medical Science Liaison, Purdue Pharma, L.P.
0401 0000 17 305 L01 P/T
Drug Store News is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.This CPE activity is approved for pharmacists and technicians and is worth 1.0 contact hours (0.1 CEUs)
Synergy Conference PBA HEALTH • PPOK • OPHA
CPE Profile Set up
2015/ 2016 Attendees
1. Visit DrugStoreNewsCE.com/pba health
2. Log in with your DSN usernameand password
New Attendees
1. Visit DrugStoreNewsCE.com
2. Create a PBA Health linked profileusing organization code: pba2015(see packet for completeinstructions)
3. Log in with your username andpassword atDrugStoreNewsCE.com/pba health
3
Synergy Conference PBA HEALTH • PPOK • OPHA
How to Submit CPE Credit• Claim CPE credits online atDrugStoreNewsCE.com/pba health
• Log in with your PBA Health linked DSNprofile
• Select the session title(s) attended fromthe or list
• Enter the session code to unlock thelesson. Complete the attestation,evaluation and submit the credit.
• CPE credit deadline: Mon, Aug. 21, 2017powered by:
Synergy Conference PBA HEALTH • PPOK • OPHASynergy Conference PBA HEALTH • PPOK • OPHA
CPE CODE:Opioids with Abuse Deterrent Properties and Claims (OADP)
Synergy Conference PBA HEALTH • PPOK • OPHA
Faculty Disclosures
KelleyWaara Wolleat
Kelley Waara Wolleat has the following disclosures to report:• Employment by Purdue Pharma, L.P.
Drug Store News has completed independent peer review processes toresolve any potential conflicts of interest in relation to this activity.
This program shall exhibit fair content balance, providing the audience with information of differentperspectives from which an informed professional opinion can be developed.
4
Synergy Conference PBA HEALTH • PPOK • OPHA
Learning Objectives Pharmacists
• Describe the importance of medications with Opioids with AbuseDeterrent Properties (OADP) .
• Review the FDA guidance provided for developers of Opioids withAbuse Deterrent Properties (OADP) medications.
• Identify resources to find Abuse Deterrent Properties and Claims• List current and future technologies studied for Opioids with AbuseDeterrent Properties (OADP) medications.
Synergy Conference PBA HEALTH • PPOK • OPHA
Learning Objectives Technicians
• Describe the importance of medications with Opioids with AbuseDeterrent Properties (OADP).
• Review the FDA guidance provided for developers of Opioids withAbuse Deterrent Properties (OADP) medications.
• Identify resources to find Abuse Deterrent Properties and Claims• List current and future technologies studied for Opioids with AbuseDeterrent Properties (OADP) medications.
12PBA Health Kansas City, MO 06/25/2017
MR 00139
Opioids withAbuse Deterrent Properties
and Claims (OADP)
Kelley Waara Wolleat, PharmD, MBAAssociate Director, Medical Science Liaison
Purdue Pharma L.P.
Overview of Emerging Technologies
All rights reserved. © 2015, Purdue Pharma L.P.
5
13PBA Health Kansas City, MO 06/25/2017
Synopsis
• This presentation will provide information about:
– The reasons OADP are important innovations
– The FDA’s direction to those developing OADP
– Where to find Abuse Deterrent Properties and Claims
– Some technologies employed or under study for OADP
2
13
14PBA Health Kansas City, MO 06/25/2017
The Problems
• Concurrent public health problems in the UnitedStates:
– Endemic nonmedical use/misuse ofprescription pain medicines
– Epidemic fatal overdoses involving opioidanalgesics
– Endemic chronic pain
14
15PBA Health Kansas City, MO 06/25/2017
National Survey on Drug Use & HealthNSDUH
• Authorized by federal statute, began in 1971• Data used to implement and measure drug policy• Annual, face to face, computer assisted interview• Approximately 70,000 persons, age 12 and older
• 2002 2014: Nonmedical use determined by:“Have you ever, even once, used any prescriptionpain reliever that was not prescribed for you, orthat you took just for the experience or feeling itcaused?”
National Survey on Drug Use and Health, Frequently Asked Questions https://nsduhweb.rti.org/respweb/faq.html Accessed 10 October 2016http://www.samhsa.gov/data/sites/default/files/NSDUH MethodSummDefs2014/NSDUH MethodSummDefs2014.htm#secc Pain Reliever UseAccessed 10/11/2016
15
6
16PBA Health Kansas City, MO 06/25/2017
Nonmedical Use (NMU)Opioid Analgesic Incidence Trends
Persons 12 y/o Initiating NMU in Past Year (%)
http://www.samhsa.gov/data/sites/default/files/NSDUH DetTabs2014/NSDUH DetTabs2014.htm#tab7 44aNational Survey on Drug Use and Health (NSDUH) Tables 7.44A&B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1.425 MM
16
17PBA Health Kansas City, MO 06/25/2017
Nonmedical Use (NMU)Opioid Analgesic Prevalence Trends
Persons 12 y/o with Current (Past Month) NMU, by Year (%)
0.0
0.5
1.0
1.5
2.0
2.5
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
http://www.samhsa.gov/data/sites/default/files/NSDUH DetTabs2014/NSDUH DetTabs2014.pdf; Tables 7.3A&B
4.325 MM
17
18PBA Health Kansas City, MO 06/25/2017
Use and MisusePrescription Pain Relievers (PPR)
• NSDUH changed some questions in 2015• Asked about any use as well asmisuse• Misuse defined only by behaviors:
– Use in any way a doctor did not direct, including use without aprescription of one’s own, use in greater amounts, more often,or longer than directed, or use in any other way not directed bya doctor.
• Change creates a break in trend for Rx drugs, but notheroin, cocaine, marijuana.
• Past Year Initiation of PPR Misuse = 2,126,000 (0.8%)• Past Year Prevalence of PPR Misuse = 12,462,000 (4.7%)• Past Month PPR Misuse = 3,775,000 (1.4%)
18
A Hughes, et al. Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. SAMHSASeptember 2016 http://www.samhsa.gov/data/sites/default/files/NSDUH FFR2 2015/NSDUH FFR2 2015.htm Accessed 10/11/2016CBHSQ (2016). 2015 National Survey on Drug Use and Health: Detailed Tables.SAMHSA, Rockville, MD. Tables 7.34A&B, 7.2 A&B, 7.3A&B
7
19PBA Health Kansas City, MO 06/25/2017
Main Reason for Last Episode ofMisuse of Prescription Pain Relievers
(2015)
* Total = 100.1%: If respondent gave more than one reason, they were prompted to indicate the most important reason.
http://www.samhsa.gov/data/sites/default/files/NSDUH DetTabs 2015/NSDUH DetTabs 2015/NSDUH DetTabs 2015.pdf Table 6.65BAccessed 10/11/2016
19
Past Year Misuse = 12,462,00097% of Respondents Provided a Reason*
Relieve PhysicalPain62.6%
12.1%
10.8%
4.4%
3.3%
2.5%2.3% 1.2% 0.9% Relieve Physical Pain, 62.6%
Feel Good Or Get High, 12.1%
Relax or Relieve Tension, 10.8%
Help With Sleep, 4.4%
Help With Feelings/Emotions, 3.3%
Experiment/See What It's Like, 2.5%
Because I Am Hooked/Have To Have It, 2.3%
Some Other Reason (Write In Responses), 1.2%
Increase/Decrease Effect of Other Drug, 0.9%
20PBA Health Kansas City, MO 06/25/2017
Sources of Pain Relievers for Most RecentMisuse (2015 Data)
* The Other category includes: “Write in responses not already listed in source table” or “Responses with insufficient information that could allow forplacement in another category.”
http://www.samhsa.gov/data/sites/default/files/NSDUH DetTabs 2015/NSDUH DetTabs 2015/NSDUH DetTabs 2015.pdf Table 6.56BAccessed 10/11/2016
20
OneDoctor,34%
MoreThan OneDoctor,1.7%
Stole fromDoctor'sOffice,Clinic,Hospital
orPharmacy,
0.7%
ThroughPrescription(s)or Stole FromHealth CareProvider,36.4%
Given orBought or TookFrom a Friendor Relative,
53.7%
Bought FromDrug Dealer orStranger, 4.9%
Some OtherWay, 4.9%
FromFriend or
Relative forFree, 40.5%
Boughtfrom Friendor Relative,
9.4%
Took fromFriend orRelativeWithoutAsking,3.8%
21PBA Health Kansas City, MO 06/25/2017
Sources of Pain Relievers for Nonmedical UseBy Frequency of NMU (Combined 2008 2011 Data)
* The Other category includes: "Wrote Fake Prescription," "Stole from Doctor's Office/Clinic/Hospital/Pharmacy," and "Some Other Way."
Sources of Prescription Opioid Pain Relievers by Frequency of Past Year Nonmedical Use: United States, 2008 2011. CM Jones, LJ Paulozzi, KA Mack.JAMA Int Med 174(5):802 3. 2014
0
10
20
30
40
50
60
70
1 29 d 30 99 d 100 199 d 200 365 d
Free: Friend/Relative
Pay: Friend/Relative
Stole: Friend/Relative
Pay: Dealer/Stranger
Rx: Physician(s)
Other
Annual Days of NMU
Percent
21
n = ~7.0MM ~2.1MM ~1.1MM~0.8MM
8
22PBA Health Kansas City, MO 06/25/2017
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
http://www.cdc.gov/nchs/data/databriefs/db166_table.pdf#1 Tables 2 and 3http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000 2014.pdfhttp://www.hhs.gov/blog/2015/12/10/rates of drug overdose deaths continue to rise.html# https://ndews.umd.edu/featuredcontent/1403
Fatal Overdoses Involving Opioids
Benzodiazepines Involved:• 1999 – 527 (13%)• 2011 – 5,188 (31%)
Synthetic Opioids other thanMethadone Involved:• 2014 – 5,544 (29%)• 79% Increase over 2013• Largely non pharmaceutical fentanyl
Methadone Involved:• 1999 – 784 (19.5%)• 2007 – 5,518 (38%)• 2011 – 4,418 (26%)
22
23PBA Health Kansas City, MO 06/25/2017
http://www.iom.edu/Reports/2011/Relieving Pain in America A Blueprint for Transforming Prevention Care Education Research/Press Release.aspxhttps://nccih.nih.gov/research/results/spotlight/081515 Nahin RL. Estimates of Pain Prevalence and Severity in Adults: United States, 2012. Journal ofPain 16(8):769 780;2015.
23
Chronic Pain is Endemic in the U.S.
Institute of Medicine of the National Academies (2011) estimates:
• “About 100 million” adult Americans experience chronic pain
• Cost range of $560 – $635 billion annually
National Health Interview Survey (2012) estimates:
• 126 million adults experience some pain in past 3 months
• 25.3 million adults suffer pain daily• 23.4 million adults experience “a lot” of pain• The 39.8 million adults with themost severe pain were more likely to:
• Have worse health status
• Suffer from disability
• Use more health care
24PBA Health Kansas City, MO 06/25/2017
http://www.cdc.gov/vitalsigns/opioid prescribing/ Vital Signs, Opioid Painkiller Prescribing, July 2014http://www.imshealth.com/en/thought leadership/ims institute/reports/use of medicines in the us 2013Medicine use and shifting costs of healthcare:A review of the use of medicines in the United States 2013; IMS Avg. Monthly ER/LA Opioid Analgesic Prevalence – data on file
24
US Centers for Disease Control & Prevention (2012)
• 259 MM prescriptions for opioids in 2012
IMS Institute for Healthcare Informatics (2012)
• ~ 75 MM persons prescribed an opioid at least once in 2012
IMS NPA Market Dynamics Monthly Opioid Average (01/16 05/16)
• ~ 13.2 MM persons on immediate release (IR) opioid analgesic
• ~ 1.7 MM persons on extended release or long acting (ER/LA) opioid
Opioid Prescriptions in the U.S.
9
25PBA Health Kansas City, MO 06/25/2017
The Federal SolutionWhite House Office of National Drug Control Policy (ONDCP)
• Rx Drug Abuse Policy Approach Is Built on Four Pillars:– Education – Prescribers and consumers– Monitoring – PDMPs and clinical monitoring of progress– Disposal – Take back programs and FDA instructions in FPIs– Enforcement – Existing laws against trafficking and pill mills
• FDA to perform expedited review of NDAs for:– analgesics with no abuse potential– abuse deterrent formulations for:
o opioid medications ando other drugs with abuse potential
• FDA to provide guidance to industry on development andassessment of potentially abuse deterrent drug formulations2
http://www.whitehouse.gov/sites/default/files/ondcp/issues content/prescription drugs/rx_abuse_plan.pdfhttp://www.whitehouse.gov/sites/default/files/ondcp/policy and research/ndcs_2014.pdf
25
26PBA Health Kansas City, MO 06/25/2017
• “FDA considers the development of these products a high publichealth priority.”
• Delineates four Categories of studies that can characterize productattributes as abuse deterrent.
• Defines “meaningful” deterrence as the standard for label claims• States that no absolute performance thresholds on studies• States that science of abuse deterrence technology and its
evaluation is relatively new and continually evolving.• Abuse Deterrent Properties and Claims will:
– Generally be based on results from studies in more than one Category– Include caveats about abuse by:
o The route(s)/method(s) of abuse it deterso Other routes/methods of abuse
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
26
Abuse Deterrent Opioids—Evaluation and Labeling
Guidance to Industry (April 2015)
27PBA Health Kansas City, MO 06/25/2017
Common Methods of Abuse
*Mechanically compromised = break, crush, grind, mill, etc.
† Intravenous or subcutaneous
Adapted from: Katz N et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. AmJ Drug Alcohol Abuse. 2011; 37:205 217.
Route Dosage Form Manipulation (if any)
Oral Intact dosage form(s) swallowed
Chewed dosage form(s) swallowed
Extract from dosage form(s) swallowed (eg, EtOH, water)
Inhaled Intact or mechanically compromised* dosage form(s) vaporized
Mechanically compromised dosage form(s) inspired into nasal cavity
Injection†Mechanically compromised dosage form(s) dissolved, usually with aid ofheat, aspirated into syringe, and injected
27
10
28PBA Health Kansas City, MO 06/25/2017
Technological Approaches to AbuseDeterrence
FDA Draft Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling. January 2013.Alexander, L. et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend. (2014),http://dx.dio.org/10.1016.j.drugalcdep.2014.02.006 (2014)
Technology Description
Physical/ChemicalBarriers
Physical barriers: can prevent chewing, crushing, cutting, grating, or grinding.Chemical barriers: can resist extraction of the opioid using common solvents like water,alcohol, or other organic solvents.These barriers can limit drug release after manipulation or change the form of the drug,rendering less amenable to abuse
Agonist/AntagonistCombinations
Antagonist added to interfere with, reduce, or defeat the euphoria associated with abuse.Antagonist may be sequestered and released only upon manipulation of the product, ie,antagonist is not clinically active when the product is swallowed but becomes active if theproduct is crushed and injected or snorted.
AversionSubstances can be combined to produce an unpleasant effect if the dosage form ismanipulated prior to ingestion or a higher dosage than directed used.
Delivery SystemCertain drug release designs or the method of drug delivery can offer resistance to abuse,eg, sustained release IM depot formulation or a subcutaneous implant.
NewMolecular Entities& Prodrugs
NME could cross BBB slowly, have atypical receptor occupancy profile, etc. Prodrugs lackopioid activity until transformed in the gastrointestinal tract and can be unattractive forintravenous injection or intranasal routes of abuse.
Combination Two or more of the above methods can be combined to deter abuse.
Novel Approaches Approaches or technologies that are not captured in the previous categories.
28
29PBA Health Kansas City, MO 06/25/2017
Evaluation of Abuse Deterrence(Study Categories Numbered per FDA Guidance)
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
29
Premarket Studies
1 In Vitro Manipulation & ExtractionEvaluate the ease of defeating physical andchemical properties of the formulation
2
3
PharmacokineticsCompare PK profiles of intact and manipulatedproduct with those of a suitable comparator
Clinical Abuse PotentialAssess abuse related measures(eg, drug liking, willingness to take again)
EpidemiologyAssess real world impact using postmarketingoutcomes data
Postmarket Studies
4
30PBA Health Kansas City, MO 06/25/2017
Hypothetical Abuse Deterrent Properties and Claims
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
Results from Studies in Category 1
[Tradename] has physical and chemical propertiesexpected to deter intravenous abuse.
30
11
31PBA Health Kansas City, MO 06/25/2017
Hypothetical Abuse Deterrent Properties and Claims
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
Results from Studies in Categories 1 & 2
[Tradename] has physical and chemical propertiesthat are expected to deter oral, nasal, and intravenous
abuse.
31
32PBA Health Kansas City, MO 06/25/2017
Hypothetical Abuse Deterrent Properties and Claims
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
Results from Studies in Categories 2 & 3
PK data demonstrate crushing results in rapidabsorption of the opioid and antagonist. These, with
results of clinical abuse potential studies, show[Tradename] has properties expected to deter oral,
nasal, and intravenous abuse.
32
33PBA Health Kansas City, MO 06/25/2017
Hypothetical Abuse Deterrent Properties and Claims
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
Results from Studies in Category 4
These data demonstrated reduced abuse of[Tradename] in the community, which appears
attributable to its formulation, which deters nasal andintravenous abuse.
33
12
34PBA Health Kansas City, MO 06/25/2017
Label Claims Also Include Caveats
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
• Examples could include:
– [Tradename] has physical and chemical properties expected todeter crushing the tablet. However, [Tradename] can still beabused by swallowing intact tablets.
– [Tradename] has properties expected to deter abuse by theoral, intranasal, and intravenous routes. However, abuse of[Tradename] by these routes is still possible.
– Additional data, including epidemiological data, when available,may provide further information on the impact of[Tradename] on the abuse liability of the drug in thecommunity. Accordingly, this section may be updated in thefuture as appropriate.
34
35PBA Health Kansas City, MO 06/25/2017
Abuse Deterrent Properties and Claims
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
Appear in Section 9.2 of a product’s FPI (or “Label”) when:
1) The drug product has attributes intended to discourage its abuse
that have undergone the studies specified by the FDA
AND
2) The results of those studies show that the drug product:
– can be expected to result in or has demonstrated ameaningfulreduction in its abuse.
35
36PBA Health Kansas City, MO 06/25/2017
Abuse Deterrent Properties and Claims inFPIs
Guidance for Industry Abuse Deterrent Opioids — Evaluation and Labeling Issued by Food and Drug AdministrationFinal Guidance issued April 2015 at : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
9. DRUG ABUSE AND DEPENDENCE
9.2 Abuse
Descriptions of selected study design, conduct, and results
Abuse Deterrence Properties and Claims currently appear inthe Summary at the end of Section 9.2
Note: Abuse Deterrent Properties in Section 9.2 of an FPI does NOTmean the product is abuse proof.
36
13
37PBA Health Kansas City, MO 06/25/2017
DailyMedThe official provider of FDA approved Full Prescribing Information (FPI) for Human and Animal Drug Products and
Biologics
https://dailymed.nlm.nih.gov/dailymed/index.cfm Screen capture 06/21/2016
37
38PBA Health Kansas City, MO 06/25/2017
Abuse Deterrent PropertiesDrugs@FDA
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
The FDA approval history of drug products now has separate bulleted designationif FDA has determined that a product has abuse deterrent properties.
38
[Tradename]
[Tradename,sponsor, and otherinformation will behere]
39PBA Health Kansas City, MO 06/25/2017
Approved Opioids*With Technology Designed to Impart Abuse Deterrence**
Technology Active Ingredients in Drug Products
Physical/ChemicalBarriers
ER: hydrocodone (2); hydromorphone; morphine; oxycodone (2);oxycodone + APAP; oxymorphone; tapentadol
Agonist AntagonistCombinations
ER: morphine + naltrexone; oxycodone + naloxoneIR: buprenorphine + naloxone† (multiple); pentazocine + naloxone
Aversion IR: diphenoxylate + atropine††
Delivery System ER: buprenorphine†
Prodrug
Combination IR: oxycodone (physical + aversive agent)
* Not all opioid drug products are indicated for use as analgesics, eg:† Indication: use in Opioid Dependence (ie, Opioid Addiction)†† Indication: Antidiarrheal
** Not all have Labeled Abuse Deterrence Properties and Claims
Alexander, L. et al. Development and impact of prescription opioid abuse deterrent formulation technologies.Drug Alcohol Depend. 138:1 6 (2014). http://www.sciencedirect.com/science/article/pii/S0376871614000611 and specific product’s FPIs
39
NB: Information Currentas of 10/10/2016
14
40PBA Health Kansas City, MO 06/25/2017
“in Development,” as used here, includes drug substances or products that are the subject of preclinical development, Investigational NewDrug applications, New Drug Applications, or Abbreviated New Drug Applications
Technology Active Ingredients in Drug Products
Physical/ChemicalBarriers
ER: levorphanol; morphine; oxycodone; oxymorphone; tapentadol
Agonist AntagonistCombinations
ER: oxycodone + naltrexone (sequestered)
Aversion IR: oxycodone + aversive agent; oxycodone/APAP + aversive agent
Delivery System ER: hydromorphone
ProdrugER: hydrocodone; hydromorphoneIR: hydrocodone; hydromorphone
Combination IR: oxycodone (physical) + aversive agent
New Chemical Entity MOR agonist with slow crossing of BBB
Opioids in DevelopmentWith Technology Designed to Impart Abuse Deterrence
40
41PBA Health Kansas City, MO 06/25/2017
Physical/Chemical Barriers Example
• Polyethylene oxide (high MW)
• Heat and pressure during manufacturing process
Difficult to crush: physicalbarrier to obtaining finepowder.
Hard to dissolve: if mixed withliquid, it turns into a viscousgel.
http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM233243.pdf Accessed 03/12/2015
41
42PBA Health Kansas City, MO 06/25/2017
Physical/Chemical Barriers(selected example)
• Drug substance binds to inactive constituents (fatty acid, waxes)within microspheres that fill a capsule.
• Each microsphere has ER properties.
http://www.collegiumpharma.com/technology platform/overview Accessed 03/11/2015
42
15
43PBA Health Kansas City, MO 06/25/2017
Agonist/Antagonist Example
• Capsule containing many pellets
• Each pellet contains ER morphine sulfate surrounding a sequesteredcore of IR naltrexone
Rate controlling membrane
Morphine sulfate
Sequestering membrane
Naltrexone
Pellets are between 1.0 1.7 mm dia.
Modified from: https://www1.pfizerpro.com/hcp/embeda/technology Accessed 03/11/2015
43
44PBA Health Kansas City, MO 06/25/2017
Agonist/Antagonist (selected example)
• Capsule contains beads
• Some beads contain ER oxycodone
• Some beads contain sequestered IRnaltrexone
• Beads are same size, color, weight,and density
• Crushing, dissolving, or extractingreleases both oxycodone andnaltrexone, blunting or preventingeuphoria from opioid agonist
Modified from: http://www.elitepharma.com/how it works/ Accessed 03/11/2015
44
45PBA Health Kansas City, MO 06/25/2017
Combination
http://acurapharm.com/platforms/aversion technology/ Accessed 03/11/2015
• Gelling agents todeter extraction andintravenous abuse
• Aversive agents todeter intranasalabuse
45
16
46PBA Health Kansas City, MO 06/25/2017
Delivery System Example
• Biodegradable, controlledrelease, implant
• Polymer blended with drugsubstance and extruded
• Can be made to have deliverytimes from weeks to months
http://www.titanpharm.com/technology Accessed 10/11/2016
46
47PBA Health Kansas City, MO 06/25/2017
Prodrug Example
• A drug substance bound to a ligand
• After oral administration, ligand is cleaved away by enzymaticaction/pH, releasing drug substance to exert effects at the receptor
L
Enzyme or pH
DS
Prodrug cannot bind to receptor
L
In vitroligation
DS
Drug binds to receptor
RDS
DrugSubstance
DS
Ligand
L
L
47
48PBA Health Kansas City, MO 06/25/2017
Draft Guidance for Generic Opioids
General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products – Guidance for Industryat http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM492172.pdf Accessed 10/11/2016 81 FR 69532(October 6, 2016) at https://www.gpo.gov/fdsys/pkg/FR 2016 10 06/pdf/2016 24234.pdf Accessed 10/11/2016
• On March 24, 2016, FDA issued a draft Guidance for generic drugdevelopers intending to submit applications for products that
reference an opioid with abuse deterrent properties.
• Comment period closed May 24, 2016.
• Public Meeting on Pre Market Evaluation of Abuse Deterrent
Properties of Opioid Drug Products – October 31 – November 1,
2016.
48
17
49PBA Health Kansas City, MO 06/25/2017
Summary
• OADP will have their maximal public health impact only whensubstantially all opioids have Abuse Deterrent Properties andClaims in their FPIs.
• Abuse deterrent technologies are one part of a comprehensiveintervention strategy to promote safe prescription opioid use
– Additional components, including governmental, community, andeducational initiatives, are also needed.
• Public and private sector policies should encourage the use ofOADP where appropriate, eg:– availability of OADP on drug formularies– removal of barriers to their use:
o higher co payso step edits
49
50PBA Health Kansas City, MO 06/25/2017
Questions about
• The reasons OADP are important innovations?
• The FDA’s direction to those developing OADP?
• Abuse Deterrent Properties and Claims in FPIs?
• The technologies considered for imparting abusedeterrence to formulations of opioid drug products?
2
50
51PBA Health Kansas City, MO 06/25/2017
MR 00139
Kelley Waara Wolleat, PharmD, MBAAssociate Director, Medical Science Liaison
Purdue Pharma L.P.
kelley.waara [email protected]
Contact Information
All rights reserved. © 2015, Purdue Pharma L.P.